Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...

Antiasthma Drugs: β2-Adrenoceptor Agonists

Antiasthma Drugs: β₂-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Antiasthma Drugs: Methylxanthines

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...

Drugs Used in Lower Respiratory Disorders: Overview

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The long-term effectiveness of specific immunotherapy in cat allergy: a real-life study.

Immunotherapy·2026

Same author

Successful oral desensitization to temozolomide in a patient with immediate hypersensitivity reaction.

Cancer chemotherapy and pharmacology·2026

Same author

Neurogenic bowel dysfunction in multiple sclerosis: clinical determinants and its association with bladder dysfunction in a multicenter study.

Archives of physical medicine and rehabilitation·2026

Same author

Redefining asthma through new immune response pattern: A clinically driven perspective.

Respiratory medicine·2026

Same author

Effects of repetitive peripheral magnetic stimulation on post-stroke upper extremity spasticity using ultrasound elastography: A randomized controlled trial.

Turkish journal of physical medicine and rehabilitation·2026

Same author

Appropriate Use of Single Inhaled Triple Therapy in Uncontrolled Asthma: A Multinational Modified Delphi Consensus.

Journal of asthma and allergy·2026

Search research articles

Related Experiment Videos

Does the combination of inhaled steroids with long acting beta2 agonists decrease the risk for osteoporosis? A 1-year

Gulden Pasaoglu¹, Haydar Gok, Dilsad Mungan

¹Department of Allergy, Ankara University School of Medicine, Ankara, Turkey.

Rheumatology International

|August 26, 2006

Summary

Inhaled corticosteroids (ICS) and combination therapy for asthma did not significantly affect bone mineral density (BMD) over one year. Combination therapy showed a nonsignificant trend towards reducing bone loss compared to single ICS use.

Related Experiment Videos

Area of Science:

Pulmonary Medicine
Endocrinology
Bone Metabolism

Background:

Inhaled corticosteroids (ICS) combined with long-acting beta2 agonists are increasingly used for moderate-severe asthma.
Data on the impact of these asthma treatments on bone loss remain inconclusive.

Purpose of the Study:

To compare the effects of single ICS versus ICS plus long-acting beta2 agonist combination therapy on bone mineral density (BMD) and bone metabolism biomarkers in adult asthma patients over one year.

Main Methods:

Forty-three adult asthma patients were divided into two groups: single ICS or combination therapy.
Bone mineral density (BMD) and biochemical markers of bone metabolism were assessed at baseline and after one year.

Main Results:

No significant differences in age or baseline BMD between groups.
A nonsignificant trend indicated less BMD decrease in the combination therapy group compared to the single ICS group.
One-year changes in BMD and bone metabolism markers did not significantly differ between the two treatment groups.

Conclusions:

Current ICS doses do not appear to significantly affect BMD changes in asthma patients.
Combination therapy suggests a potential, albeit nonsignificant, trend in reducing bone loss.
Further research is required to confirm if combination therapy can minimize bone loss.